The DOI matches its Crossref record; the references it cites are not checked yet.
Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus
Abstract
adult worldwide. Type 2 diabetes mellitus (T2DM) confers a 2- to 3-fold increased risk of cardiovascular (CV) events compared with non-diabetic patients, and CV mortality is responsible for around 80% mortality in this population. Patients with T2DM can have other features of insulin resistance-metabolic syndrome like hypertension, lipid abnormalities, and obesity which are all associated with increased CV disease and stroke risk even in the absence of T2DM. The management of a T2DM calls for employing a holistic risk factor control approach. Metformin is the first line therapy for T2DM and has been shown to have cardiovascular beneficial effects. Intense debate regarding the risk of myocardial infarction with rosiglitazone led to regulatory agencies necessitating cardiovascular outcome trials with upcoming anti-diabetic medications. Glucagon like peptide-1 agonists and sodium glucose co-transporter-2 inhibitors have shown promising CV safety and additional CV benefit in recent clinical trials. These drugs have favorable effects on traditional CV risk factors. The findings from these studies further support that fact that CV risk factor control plays an important role in reducing morbidity and mortality in T2DM patients. This review article will discuss briefly the cardiovascular safety and benefits of the oral medications which are currently being used for T2DM and will then discuss in detail about the newer medications being investigated for the treatment of T2DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the risk of patients developing cardiovascular and renal events increase as DM and CKD progresses, potentially reaching renal and cardiac endpoint events such as ESRD, heart failure, myocardial infarction (MI) and stroke [11–14].”
Citations
The citation lists are queued
They are fetched later and appear here then.
References 106 · Cited by 50
Research works printed but not linked: 4
- Azimova K, 2014, Ochsner J, 14, 616
- 10.1001/archinte.1997.00440290014001 · doi:10.1001/archinte.1997.00440290014001
- White WB, 2013, Presented at European Association for the Study of Diabetes
- Kosiborod M, 2017, Presented at American College of Cardiology Scientific Sessions
Metadata
- Authors
- Yandrapalli, S., Jolly, G., Horblitt, A., Sanaani, A., & Aronow, W. S.
- Affiliations
- Westchester Medical Center (US)
- Corresponding author
- Aronow, Wilbert S.
- Venue
- Postgraduate Medicine
- Publisher
- Informa UK Limited
- Published
- 2017-07-27
- Volume
- 129
- Issue
- 8
- Pages
- 811-821
- ISSN
- 0032-5481 (ISSN-L)
- 1941-9260
- OpenAlex
- W2741341764
- Cited by
- 50
- References
- 106
- Citations by year
- 2026: 1 · 2025: 3 · 2022: 7 · 2021: 8 · 2020: 12 · 2019: 8 · 2018: 7 · 2017: 2
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Postgraduate Medicine (publishedVersion)
- PubMed (publishedVersion)
- Touro Scholar (Touro College) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cardiovascular risk, cardiovascular safety, cardiovascular outcomes, metformin, rosiglitazone, cardiovascular outcome trials, GLP-1 receptor agonists, SGLT2 inhibitors, cardiovascular risk management, insulin resistance, metabolic syndrome
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Benzamides, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Humans, Hypoglycemic Agents, Metformin, Risk Factors, Sulfonylurea Compounds, Randomized Controlled Trials as Topic, Thiazolidinediones, Dipeptidyl-Peptidase IV Inhibitors, Glycoside Hydrolase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1080/00325481.2017.1358064
- The paper
- Yandrapalli, S., Jolly, G., Horblitt, A., Sanaani, A., & Aronow, W. S. (2017). Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. Postgraduate Medicine. https://doi.org/10.1080/00325481.2017.1358064
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.